ViralClear to Host Conference Call on September 22, 2020, to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Soluti...
September 09 2020 - 12:16PM
- Randomized, Double-Blind, Placebo-Controlled, Clinical
Trial of Merimepodib in Combination with Remdesivir in Hospitalized
Adults with COVID-19 Who Require Non-Invasive Ventilation/High Flow
Oxygen Devices or Supplemental Oxygen
BioSig Technologies, Inc.’s (Nasdaq: BSGM) (“BioSig” or the
“Company”) subsidiary, ViralClear Pharmaceuticals, Inc.
(ViralClear), today announced that it will host a conference call
to discuss its Phase 2 clinical trial. The study is a
randomized, double-blind, placebo-controlled trial evaluating the
efficacy and safety of merimepodib (MMPD) in combination with
remdesivir for hospitalized adult patients who have confirmed
infection with SARS-CoV-2 and require non-invasive ventilation/high
flow oxygen devices or supplemental oxygen (score of 3 or 4,
respectively, on the NIAID 8-point ordinal scale). The trial
is being conducted at 5 investigational sites across the United
States (US), with Dr. Andrew Badley, the chair of Mayo Clinic
COVID-19 Research Task Force serving as the study director.
Conference Call Details:Date: Tuesday,
September 22, 2020Time: 11:00 AM Eastern Time (ET)Dial in Number:
877-407-8293 / 201-689-8349. A replay will be available for two
weeks starting on September 22, 2020, at approximately 3:00 PM ET.
To access the replay, please dial 877-660-6853 / 201-612-7415. The
conference ID# is 13709930.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About Merimepodib and ViralClear
BioSig’s Technologies, Inc (Nasdaq: BSGM) subsidiary,
ViralClear Pharmaceuticals, Inc. (ViralClear), is seeking to
develop a novel pharmaceutical called merimepodib to treat patients
with COVID-19. Merimepodib is intended to be orally administered,
and has demonstrated broad-spectrum in vitro antiviral activity,
including strong activity against SARS-CoV-2 in cell cultures.
Merimepodib was previously in development as a treatment for
chronic hepatitis C and psoriasis by Vertex Pharmaceuticals
Incorporated (Vertex), with 12 clinical trials (7 in phase 1 and 5
in phase 2) with over 400 subjects and patients and an extensive
preclinical safety package was completed.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024